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S
IGNIFICANT PROGRESS HAS been made in endovascular technologies during the past decade that has drastically altered the treatment paradigm for patients with femoropopliteal occlusive disease. Catheter-based endoluminal treatment modalities have gained wide acceptance, with proven clinical efficacy for patients suffering from peripheral arterial disease. Surgical revascularization of the lower leg, although once considered the standard of treatment for femoropopliteal occlusive disease, is performed less frequently and catheter-based interventions have become the initial treatment of choice in patients with intermittent claudication or critical limb ischemia. The primary impetus of percutaneous interventions include rapid recovery with minimally invasive endoluminal interventions, less postprocedural discomfort with outpatient treatment, and a high technical success rate, even in long-segment femoropopliteal occlusive disease. [1] [2] [3] Despite these perceived advantages with endovascular treatments, late clinical failure due to restenosis or arterial occlusion remains a shortcoming of percutaneous catheter-based interventions. [4] [5] [6] Because of the proven durability with lower-extremity surgical revascularization using autologous vein grafts, 7 treatment indications and patient selection using endovascular strategies in patients for lower-extremity occlusive disease remain a subject of debate.
In 2000, a comprehensive standard of treatment guideline for peripheral arterial disease was published by a multidisciplinary TransAtlantic Inter-Society Consensus (TASC I) working group, which consisted of various US and European medical societies. 8 This report underscored a shift of treatment paradigm from conventional surgical revascularization to endovascular strategies for lower-extremity arterial occlusive disease with therapeutic considerations based on disease pattern and morphological stratification. For femoropopliteal artery occlusive disease, for instance, the report recommended the endovascular procedure for type A lesion, which represents short-segment occlusive disease, and surgical bypass for type D lesion, which represents long-segment femoral artery occlusion. In 2007, updated treatment guidelines of TASC II report were published, which further refined treatment guidelines based on morphological stratification for aortoiliac and femoropopliteal occlusive disease. 9 Lesion stratification of femoropopliteal occlusive disease in TASC I and TASC II are displayed in Table 1 . With continuous advances in imaging equipment and endovascular technolo-gies, minimally invasive techniques have become the mainstay treatment strategy for all types of femoropopliteal occlusive disease. In the TASC II report, treatment recommendations for femoropopliteal disease remain similar to the TASC I guideline. It is noteworthy that TASC I guidelines did not offer definitive treatment recommendations for type B or C lesions, due in part to lack of sufficient clinical evidence. In contrast, TASC II guidelines recommended endovascular treatment as the initial treatment approach for type B lesions and surgical treatment as the initial strategy for type C lesion. 9, 10 These treatment recommendations reflect a trend based on increased evidence-based literature supporting endovascular treatment of superficial femoral artery (SFA) occlusive disease. Sifting through all available literature on endovascular treatment of peripheral arterial disease for a comprehensive analysis is a daunting and overwhelming challenge. In this article, we review contemporary clinical data on endovascular stent placement for femoropopliteal occlusive disease. Commonly encountered pitfalls and challenges in interpreting clinical data regarding lowerextremity intraluminal stenting are discussed. Clinical evaluation is focused primarily on prospective randomized trials on femoropopliteal endoluminal stenting treatment. Treatment outcomes on clinical trials relating to adjunctive stenting strategies, such as drug-eluting stenting or self-expanding stent grafting of femoropopliteal occlusive disease are also discussed.
Challenges

Associated with Data Interpretation of SFA Stenting
The current literature is inundated with countless clinical reports about endovascular treatment of femoropopliteal arterial occlusive disease. A brief search of the MEDLINE database using key phrases of femoral artery and stent in February 2010 yielded Ͼ1,600 articles pertaining to endovascular treatment of infrainguinal peripheral arterial disease. Analysis of this large volume of literature of catheter-based SFA interventions with a hope of determining an optimal treatment strategy can be both daunting and intimidating. The lack of definitive treatment strategies regarding infrainguinal arterial occlusive disease is reflected by various factors, including heterogenous anatomical variable of SFA and technological limitation of stenting. Other confounding variables that contributed to the therapeutic challenges of SFA stenting include complexity of medical comorbidities of these patients and outflow status of infrapopliteal circulation. One must bear in mind the implications of these variables when analyzing literature about endovascular SFA interventions.
The anatomical territory of the SFA represents the most challenging vascular region in the body for catheter-based interventions. This is the longest artery with fewest side branches in the arterial circulation and is fixed between two major flexion joints, the hip and the knee. Multiple geometric forces exerted on the SFA during routine movements, such as sitting, walking, or jogging. These forces include longitudinal and lateral compression, flexion, elongation, and torsion. Additionally, the distal segment of the artery traverses through a narrow adductor canal, or Hunter canal, marked by the junction of aponeurosis of the vastus medialis, the adductor longus, and the sartorius muscle. This anatomical canal exerts further external compression on the SFA during exercise due, in part, to thigh muscle contraction. Any catheter-based intervention with balloon angioplasty or stenting of the distal SFA involving the adductor canal, where repetitive compressive force can result in extensive scar formation, can potentially lead to arterial stenosis or thrombosis resulting in endovascular treatment failure. 4, 6, [11] [12] [13] Consequently, stent fracture is a well-characterized treatment failure following SFA interventions, caused in part by the repetitive mechanical forces exerted on this long artery. 4, 6, [11] [12] [13] Although a new generation of stent design and metal strut material have overcome these mechanical issues that can lead to stent fracture, the clinical durability of this new generation of femoropopliteal stent remains to be proven. Another important variable when analyzing clinical outcomes of SFA interventions relates to the rapidly evolving endovascular technologies, as well as the ever-changing field of treatment modalities. Early experience with balloon angioplasty of the SFA showed poor outcomes with high restenosis rate caused by arterial elastic recoil. 10, 14 Researchers subsequently reported the use of balloon-expandable stents in the femoropopliteal segment, in which the treatment outcomes were equally dismal because of the high incidence of crushed or fractured stent caused by external forces. 11, 14, 15 The introduction of self-expanding stent invigorated researcher's interest in SFA interventions. Clinical experience with selfexpanding Elgiloy stents or WALLSTENTs (Boston Scientific, Natick, MA), in the treatment of lengthy femoropopliteal disease or lesions unresponsive to balloon angioplasty showed acceptable immediate results, but low midterm patency with a high rate of stent thrombosis and fractures. 13, 16 The introduction of self-expanding nitinol stents was viewed by many researchers as the ideal endovascular treatment modality for SFA because of the improved radial strength and shape-memory metal properties, which can be crush-resistant and able to counterbalance the external arterial compressive forces. 15, 17 However, clinical reports of SFA nitinol stenting have shown mixed treatment outcomes, with failure modes attributed to stent design issues or stent strut configuration. [11] [12] [13] 16 More recently, researchers have reported early promising results with the use of stent graft or drug-eluting stent (DES) in SFA disease to reduce recurrent stenosis. [18] [19] [20] Although the availability of these varying endovascular technologies marks an exciting field for interventionalists, analysis of current literature to determine an ideal treatment strategy for femoropopliteal disease is an insurmountable challenge because of the paucity of controlled randomized trials.
Other confounding variables that play a crucial role in the treatment outcomes of SFA interventions relate to postintervention anticoagulation regimen and infrapopliteal runoff vessel status. Intraluminal stent placement triggers immediate prothrombotic cascades, including initial platelet deposition, which is followed by thrombin activation, fibrin deposition, and ultimately thrombus formation. 21, 22 The importance of continual anticoagulation is critical in reducing this procoagulant cascade and maintain stent patency. However, the ideal anticoagulant of choice as well as duration of anticoagulation remains a subject of debate. Clinical efficacy of anticoagulation with clopidogrel has been reported by several researchers after femoropopliteal intervention, with varying treatment durations from 3 to 12 months or longer. 23, 24 Additionally, the presence of underlying medical comorbidities, such as hypertension, hypercholesterolemia, diabetes, and renal insufficiency are common in patients with femoropopliteal artery occlusive disease. The impact of these confounding medical conditions on treatment outcomes of SFA interventions has been highlighted by many investigators. 5, [25] [26] [27] Lastly, anatomical factors, such as proximal aortoiliac inflow status and distal outflow tibial runoff circulation can similarly affect the treatment outcomes of SFA interventions. It is wellknown that long-term patency following SFA balloon angioplasty decreases according to the lesion length, as long-segment occlusive lesion is associated with worse outcomes. Similarly, the status of runoff vessel is adversely related to SFA patency following balloon angioplasty, as three-vessel runoff is consistently associated with improved patency compared to single-vessel runoff. 6, 14, 28, 29 Considerations of these medical comorbidities and anatomical variables must be taken into account when analyzing the efficacy of femoropopliteal interventions in patients with peripheral arterial occlusive disease.
US Food and Drug Administration؊Approved Devices for Femoral Artery Implantation
Currently, there are two nitinol stents that have received US Food and Drug Administration (FDA) approval for treatment of femoropopliteal artery occlusive disease. The IntraCoil Self-Expanding Peripheral Stent (Sulzer IntraTherapeutics, St. Paul, MN), consisting of a single coil-shaped nitinol spiral wire, became the first stent to receive FDA approval for femoropopliteal application in April 2002. 30, 31 The LifeStent (Bard, Tempe, AZ) was subsequently approved for femoropopliteal implantation in February 2009. The spiral-shaped IntraCoil stent, although unique in design compared to the conventional intraluminal stent, never gained wide clinical acceptance because of a high rate of stent-related restenosis and thrombosis. [30] [31] [32] In contrast, several bare nitinol stents from a variety of manufacturers, with approval for either biliary or iliac artery indications, are frequently being used by physicians for femoropopliteal occlusive disease in an offlabel manner while their respective clinical trials are underway seeking FDA approval for SFA implantation. 33, 34 In May 2005, the FDA issued an approval of a flexible self-expanding covered stent Viabahn endoprosthesis (W.L. Gore and Assoc., Flagstaff, AZ) for SFA deployment, which further ex-panded the armamentarium for endovascular intervention of femoropopliteal occlusive disease. This flexible covered stent consists of an expanded polytetrafluoroethylene (ePTFE) lining with an external nitinol support extending along its entire length. Clinical application of this endoluminal covered stent have been widely expanded in both femoropopliteal occlusive disease and popliteal artery aneurysm with remarkable short-term success rate. [35] [36] [37] [38] 
Data Analysis of Literature of SFA Interventions
Given the innumerable clinical reports on SFA interventions with endoprosthesis, efforts to analyze all published literature about the clinical efficacy of this treatment modality are both unrealistic and daunting. Therefore, our focus in this literature analysis will be based on clinical reports of femoral artery interventions with (1) bare metal stent placement, (2) DES applications, and (3) stent-graft implantation. Particular attention will be focused on prospective and randomized trials or registries that evaluated the clinical efficacy of these endovascular treatment modalities.
Clinical Evidence of SFA Stent Placement
As one of the FDA-approved nitinol stents for femoropopliteal implantation, the LifeStent (Bard) received its regulatory approval based primarily on a prospective multicenter RESILIENT trial, also known as the Randomized Study Comparing the Edwards Self-Expanding LifeStent Versus Angioplasty-Alone in Lesions Involving the SFA and/or Proximal Popliteal Artery. 39 During the phase I feasibility and safety study, the RESILIENT trial enrolled patients with claudication due to femoropopliteal occlusive lesions, the treatment strategy of which included either self-expanding nitinol LifeStent implantation or balloon angioplasty with optional adjunctive stenting. 39 The anatomical lesion inclusion criteria included total lesion length Ͻ15 cm and vessel size between 4.0 and 6.5 cm in diameter. The outcomes of this milestone study revealed statistically superior results using the LifeStent versus balloon angioplasty alone in treating the femoropopliteal occlusive disease. During the RISILIENT phase II pivotal trial, 206 patients were randomized in a 2:1 ratio to either primary LifeStent placement (n ϭ 134) or Percutaneous Transluminal Angioplasty (PTA) with optional adjunctive stenting (n ϭ 72). The trial protocol allowed for treatment of more than one lesion per patient as long as the total lesion length did not exceed 15 cm. The mean lesion length in this study was 6.5 cm. The primary endpoint of RESILIENT was target vessel revascularization and/or target lesion revascularization (TLR) at 6 months. The 12-month restenosis rate by ultrasound surveillance confirmed the superiority of primary stenting to PTA cohorts, with patency of 80% and 38%, respectively. 39 With ongoing ultrasound surveillance per trial protocols, it is anticipated that the 2-year outcomes from the phase II trial should provide additional support for the advantage of primary stenting over PTA in the treatment of SFA lesions. Additionally, the long-term RESILIENT trial should uncover the incidence of stent fracture using the second-generation flexible nitinol LifeStent and provide long-term profile on its safety outcomes. 39 Schillinger and associates conducted the first randomized controlled trial comparing primary stenting with self-expanding nitinol stents to balloon angioplasty with provisional stenting for treatment of femoropopliteal obstructions in patients with peripheral arterial disease. 40 These researchers randomized 104 patients with severe claudication or chronic limb ischemia who had SFA stenosis or occlusion to either primary stent implantation (n ϭ 51) or balloon angioplasty with optional stenting (PTA, n ϭ 53). In the latter patient group, secondary SFA stenting was permitted in case of suboptimal or failed balloon angioplasty, as defined by residual stenosis Ͼ30% of luminal diameter, early elastic recoil, or flow-limiting dissection. Average lengths of the treated segments in the stenting and PTA group were 132 Ϯ 71 mm and 127 Ϯ 55 mm, respectively. In the PTA group, secondary stenting was performed in 17 of 53 patients (32%) due to a suboptimal result; however, these patients were analyzed in the balloon angioplasty group as part of the intention-to-treat analysis. The primary study endpoint was the binary angiographic restenosis rate at 6 months, while secondary endpoints were restenosis rates by duplex ultrasound at 3, 6, and 12 months and clinical and hemodynamic outcomes. Angiographically detected restenosis rates at 6 months in the stenting and PTA groups were 23.5% and 43.4% (P ϭ .05), respectively. At 12 months, ultrasounddetected restenosis rates in the stenting and PTA groups were 36.7% and 63.5% (P ϭ .01). Clinically, patients in the stent group had a significantly higher maximum treadmill walking capacity compared to the PTA group at 6 and 12 months. Similarly, ankle-brachial indexes were significantly improved in patients treated with primary stenting compared to PTA intervention. Based on study results with 12-month follow-up data, the authors concluded that primary stenting improved morphological and clinical outcomes in these patients, with a median SFA lesion length of 10 cm compared to PTA treatment. 40 The authors subsequently reported the 2-year mid-term outcomes of this randomized trial, which confirmed a sustained benefit of primary nitinol stenting compared to PTA with optional stenting. 41 The 24-month restenosis rates in the stenting and PTA group were 49.2% and 74.3% (P ϭ .03), respectively. Additionally, patients in the stenting group showed a trend toward better treadmill walking capacity (average 302 v 196 m; P ϭ .12) and better ankle brachial index values (average 0.88 v 0.78; P ϭ .09) at 2 years, respectively. The clinical benefit of SFA stenting compared to PTA in patients with femoropopliteal occlusive disease at 2 years is clearly demonstrated in this randomized controlled trial. 41 In another randomized controlled study that compared primary stenting to balloon angioplasty in patients with femoropopliteal occlusive disease, Krankenberg and associates randomized 244 patients to either primary stenting with selfexpanding nitinol stent (n ϭ 123) or balloon angioplasty (n ϭ 121) with optional adjunctive stent placement when technical failure persisted after repeat angioplasty. 42 In this Femoral Artery Stenting Trial (FAST), mean SFA lesion length was between 4 and 5 cm in both groups. Technical success rates in the stenting and PTA group were 95% and 79%, respectively. At 12 months, however, restenosis rates in the stenting and PTA group were 32% and 39%, respectively; a difference that was not statistically significant. TLR was 14.9% for the primary stenting patients versus 18.3% for the PTA patients (P ϭ .595), and the resting ankle-brachial index improved by 0.21 for the primary stenting patients versus 0.15 for the PTA patients (P ϭ .560). Remarkably, all subgroup analyses, including presence/absence of diabetes, long versus short lesions, and stenosis versus occlusions, yielded trends but no significant benefit of primary stenting. Based on treatment outcomes at 1 year, the authors concluded that balloon angioplasty in short femoropopliteal lesions (Ͻ10 cm in length) can result in similar clinical efficacy compared to primary stenting with respect to restenosis prevention. 42 Although many researchers have praised the clinical benefit of SFA stenting for patients with claudication or ischemic rest pain, complications associated with SFA stenting have also been reported, including stent fracture, in-stent restenosis, and stent occlusion due to intimal hyperplasia. 13, 43 The observation of stent fracture following SFA implantation became an increasingly recognized phenomenon reported by many researchers. 13, 43 The first systematic evaluation of SFA stent fractures was addressed in a double-blind, randomized, prospective trial by Duda and colleagues. 44 In the SirolimusCoated Cordis SMART Nitinol Self-Expandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease (SIROCCO I) trial, the primary endpoint of the study was the in-stent mean percent diameter stenosis as measured by quantitative angiography at 6 months. At 12 months in this series, SFA stent fractures were found in 31% of the patients, with a mean stent length of 85 mm and a maximum of three stents implanted. Due in part to the high incidence of stent fracture rate in this trial, the authors modified the study design in the SIROCCO II trial in which a maximum of only two SFA stents were allowed in both treatment groups. 45 The result of this trial showed a marked reduction of stent fracture rate to 11% at a mean stented length of 82 mm. 45 Because researchers have reported a wide range of stent fracture rates after SFA implantation, it appears that stent fracture may be influenced in part by different stent design, stent length, and vessel stress resistance. 43, 46, 47 Schlager and associates analyzed the incidence of stent fractures of 286 patients who underwent SFA stenting during a 5-year period. 13 The authors reported SFA fracture rates were 19% for WALLSTENT (Boston Scientific) after a mean of 43 months, 28% for SMART stent (Cordis) after a mean 32 months, and 2% for Dynalink/Absolute stent after a mean 15 months. 13 In a nonrandomized registry study, Scheinert and colleagues analyzed the SFA stent fracture in 93 patients with 261 SFA stents and noted remarkable differences in stent fracture rate between various products and stented segments. 46 Overall, SFA stent fracture rate was 24.5% (64 of 261 stents). Specifically, stent fracture was classified as minor (single strut fracture) in 31 cases (48.4%), moderate (fracture of more than one strut) in 17 cases (26.6%), and severe (complete separation of stent segments) in 16 cases (25.0%). With respect to the length of SFA stenting, stent fracture rates were 13.2% for stented length Յ8 cm, 42.4% for stented length Ͼ8 to 16 cm, and 52.0% for stented length Ͼ16 cm. 46 Based on these experiences with early-generation nitinol stent designs, stent manufacturers have dramatically improved the stent design to produce "fracture-free" stents so the device can withstand the rigorous mechanical forces in the femoropopliteal segment.
Clinical Evidence of SFA DES Placement
Clinical efficacy of DES has been irrefutable in the treatment of coronary artery disease, as multiple randomized controlled trials have validated its benefit in patients with myocardial ischemia. 48, 49 Many researchers have anticipated that similar clinical efficacy using DES can be reproduced in patients with lower-extremity peripheral arterial disease. Undoubtedly, the concept of combining the advantages of mechanical nitinol scaffolding with the antiproliferative action of drugs creates a novel treatment strategy in patients with femoropopliteal occlusive disease. However, clinical studies have yet to demonstrate long-term benefits with DES implantation in patients with femoropopliteal occlusive disease. The disappointing study outcomes may be due in part to underpowered sample size, as well as the complexity of drug elusion in SFA stent design. 44, 45 Duda and associates conducted the first human clinical trial to evaluate the feasibility and safety of DES for treatment of SFA occlusive disease. 44 In this randomized multicenter SIROCCO trial, the researcher compared sirolimus-eluting SMART stent (Johnson & Johnson; n ϭ 18, mean lesion length 85 mm, 69% total occlusions) versus noncoated SMART stent (Johnson & Johnson; n ϭ 18, mean lesion length 81 mm, 57% total occlusions). 44 Initial results with 6-month follow-up showed similar restenosis rates between the sirolimus-eluting stent group and uncoated stent group, which were 22.6% and 30.9%, respectively (P Ͼ .05). Additionally, there was a higher in-stent mean lumen diameter in patients treated with the DES (4.95 mm) than in patients treated with the bare metal stent (4.31 mm; P Ͻ .05). Results from the SIROCCO I trial led the authors to conclude that sirolimus-eluting SMART stent for SFA occlusive disease is safe and feasible without associated adverse sequelae compared to noncoated bare stents. 44 In a subsequent follow-up analysis at 9 and 18 months of these SIROCCO I results, the researcher discovered that five patients who had received a slow-release form of the sirolimus-eluting stent appeared to have less restenosis than patients who had received either a fast-release form of the sirolimus-eluting stent or a bare metal stent. 44, 50 The authors noted that overall improvements in ankle-brachial index in the sirolimus group and the bare stent group were similar, which were 0.96 and 0.87, respectively (P Ͼ .05). Similarly, the binary restenosis rate by duplex ultrasound in the sirolimus group and the bare stent group were equivalent, 22.9% and 21.1%, respectively (P Ͼ .05). Lastly, other pertinent study endpoints such as TLR, target vessel revascularization, and mortality rates at 24 months did not differ significantly between the two groups. The authors concluded that sirolimus-eluting stent did not confer any clinical advantage in restenosis rate compared to bare stent treatment in SFA occlusive disease. 44, 45, 50 The same investigators conducted the SIROCCO II randomized controlled trial in which 57 patients with SFA occlusions or stenoses were randomized to either a slow-release form (the release was still much faster than that for the sirolimus-eluting coronary platform) of sirolimus-eluting SMART stent or a bare SMART stent. 45 Because six patients from the SIROCCO I trial developed stent fractures because of three or more overlapping SFA stents, the researchers allowed a maximum of only two stents per patient in the SIROCCO II trial to treat SFA lesions with an average length of 81.5 mm. 45 A 24-month follow-up study of all 93 patients randomized in the SIROCCO trial, including 47 randomized to the sirolimus-eluting SMART stent and 46 to the bare stent, both stents performed similarly without significant difference in patency or safety profile. 50 A surprising finding from the SIROCCO trial was the relatively high patency rate of the bare metal self-expanding SMART stent in SFA occlusive lesions, whereby the in-stent restenosis rate at 24 months was 21.1% based on ultrasound duplex surveillance (Table 2) . 50 Notwithstanding the findings from the SIROCCO trial, which revealed no clinical superiority of DES compared to bare metal stents, researchers are pursuing clinical investigations on other antiproliferative pharmacological platform in drug-eluting stent technologies for femoropopliteal occlusive disease. In the STRIDES (SFA Treatment with Drug-Eluting Stents) trial, the researchers plan to evaluate an everolimuscoated stent in a nonrandomized prospective setting with anticipated enrollment of 100 patients from 14 European sites. 1, 20 Everolimus-coated SFA stents 6 mm and 8 mm in diameter will be deployed in patients with symptomatic SFA lesions Ͼ50% luminal stenosis with lesion lengths ranging from 3 to 17 cm in length. Sponsored by Abbott Laboratories (North Chicago, IL), the trial's primary endpoint is binary in-stent restenosis in the stented SFA at 6 months. Secondary endpoints include angiographic restenosis at 12 months, as well as 5-year clinical follow-up to track resolution of femoropopliteal ischemic symptoms, limb preservation, and patient survival. 1, 20 In a separate clinical study that evaluates a different DES technology, the ZILVER (Evaluation of the Zilver PTX DrugEluting Stent in the Above-the-Knee Femoropopliteal Artery) trial uses a nonpolymer technology and a paclitaxel-coated stent (Zilver PTX stent; Cook, Bloomington, IN) in a randomized setting. 1, 2 Sponsored by Cook Medical (Bloomington, IN), this paclitaxel-coated stent has no polymer coating to bind the active drug to the stent, in contrast to the firstgeneration coronary sirolimus-eluting and paclitaxel-eluting stents. Paclitaxel is hydrophobic, lipophilic, and highly protein-bound, with a long tissue residence time (Ͼ2 months). Researchers postulate that by using this polymer-free DES technology, there will be minimal washout following stent implantation and that the drug will then be taken up avidly by the diseased artery. Clinical investigations of the paclitaxelcoated stent will encompass a multicenter randomized trial with a 480-patient enrollment, as well as a global registry of an additional 794 patients treated with Zilver PTX stents for femoropopliteal occlusive disease. 1, 20, 51 In the preliminary report of the 794 patients who were enrolled in the global registry (mean lesion length 9.6 cm), 36% had diabetes, 55% had hypercholesterolemia, 80% had hypertension, and 79% were past or current smokers. 52 Among these registry patients, 435 patients had 6-month interim follow-up data, including event-free survival rate, freedom from TLR, and stent fracture rate, which were 94%, 96%, and 1%, respectively. There were 200 patients with available 12-month interim follow-up data, including event-free survival rate, freedom from TLR, and stent fracture rate, which were 84%, 88%, and 2%, respectively. 52 
Clinical Evidence of SFA Covered-Stent Placement
The use of a covered stent in vascular pathology was introduced nearly 2 decades ago when researchers created homemade stent graft for arterial aneurysm exclusion and traumatic injury coverage. [53] [54] [55] Since then, the covered stent has been developed specifically for the treatment of infrainguinal atherosclerotic occlusive disease. The Viabahn endoprosthesis (W.L. Gore and Assoc.), which was approved by the FDA in June 2005 for SFA implantation, remains the only FDAapproved covered stent for intra-arterial application. This is a flexible, self-expanding endoluminal graft consisting of an external nitinol stent support skeleton along with an ePTFE lining material covering the entire stent length. The Viabahn endoprosthesis has received numerous clinical evaluations to validate its clinical efficacy in femoropopliteal occlusive disease. 18, 19, 35, 37, 38, 56, 57 Since its initial introduction for clinical application, the Viabahn device has had several design modifications to lower its device profile and enhance fabric edge conformability. 18, 35 These device modifications, along with better a understanding of appropriate patient selection, has resulted in improved clinical outcomes in the treatment of femoropopliteal occlusive disease. 35, 36 Lammer and associates conducted the first prospective multicenter feasibility trials encompassing 17 international institutions to evaluate the safety and feasibility of covered stent Hemobahn (W.L. Gore and Assoc.), which is the European version of Viabahn device. 58 A total of 127 patients with symptomatic peripheral arterial occlusive disease were included in this trial. Among them, Hemobahn-covered stents were used in 61 symptomatic iliac stenosis and 80 symptomatic SFA disease, respectively. 58 Mean length of the Hemobahn used in the SFA was 13.1 cm (62% of the lesions were Ͼ10 cm long) and the mean diameter was 6.3 mm. Technical success of Hemobahn deployment was achieved in all patients. Complications occurred in 24 of 141 procedures (3 were classified as major complications). Early 30-day device thrombosis occurred in three SFA and one iliac artery. Late restenosis or reocclusion was observed in 5 iliac and 14 femoral arteries within the first year. Cumulative primary patency rates based by duplex ultrasound evaluation in femoral arteries were 89.7% at 6 months and 78.7% at 12 months following device implantation. The authors reported a remarkable cumulative secondary patency rate of 93.4% at 12 months. 58 The encouraging study outcomes from this European trial subsequently led to a prospective randomized multicenter US trial that compared balloon angioplasty versus primary Viabahn-covered stent implantation in 197 patients with symptomatic SFA lesions due to either chronic limb ischemia or disabling claudication. 19 The mean lesion length was 7 cm and vessel caliber ranged between 4.8 and 12 mm in diameter. The technical success rate was 95% for the Viabahn group, in contrast to 66% for the PTA-only group (P Ͻ .0001). There were no differences between the Viabahn or PTA groups in either early or late adverse events. The most common minor adverse events were early hematoma and pain, which occurred more frequently in the stent-graft patients. The primary patency by duplex ultrasound assessment was 65% for the Viabahn patients versus 40% for the PTAonly patients at 12 months (P ϭ .0003). Among patients with chronic limb ischemia, specifically, there was a further 15% symptomatic improvement in patients treated with Viabahn compared to PTA treatment cohorts at 12 months (P ϭ .003). 19 The finding of this prospective randomized trial formed the basis for clinical evidence by which the FDA granted its approval for Viabahn in the treatment of SFA atherosclerotic occlusive disease.
Primary Viabahn stent-graft implantation was compared with above-knee femoropopliteal artery bypass with prosthetic bypass in a single-center prospective randomized trial in 86 patients with arterial ischemia whose symptoms ranged from claudication to rest pain, with or without tissue loss. 56 The authors randomized the treatment of SFA occlusive disease with the Viabahn stent graft (n ϭ 50) to surgical femoropopliteal above-knee bypass with synthetic graft material (n ϭ 50). 56 The mean distance of SFA implantation using the Viabahn endoprosthesis was 25.6 cm in patients who received the stent-graft treatment. It is noteworthy that the length of SFA coverage in this trial was considerably longer compared to all other randomized controlled trials evaluating SFA nitinol stent implantation. There was no difference in the 12-month primary patency rate between the Viabahn and bypass group, which was 73.5% and 74.2%, respectively. The authors concluded that Viabahn stent graft is an effective treatment strategy for patients with femoropopliteal occlusive disease, as this minimally invasive strategy provided comparable outcomes at 1 year compared to surgical bypass (Table 3) . 56 These researchers recently reported their 2-year follow-up data on this randomized comparison of Viabahn stent graft versus prosthetic femoropopliteal artery bypass. 59 The primary or secondary patency rates between the Viabahn stent graft or bypass graft group were similar during the 2-year follow-up period ( Table 3 ). The 2-year primary patency rates between the Viabahn and bypass groups were 63% and 64%, respectively, while the secondary patency rates between the two groups were 74% and 76%, respec- tively. An interesting result emerged when authors analyzed the patency rates based on the Viabahn device size in which larger stent graft size between 6 and 7 mm in diameter yielded superior patency at 24 months compared to stent graft size 5 mm in diameter (Table 4) . Not surprisingly, the treatment outcomes based on TASC II lesion classification consistently showed superior treatment outcomes in shorter disease, as in TASC II A or B lesions, in contrast to long stenosis, as in TASC II C or D lesions ( Table 4 ). The authors concluded that primary stent-grafting using Viabahn produced similar clinical success compared to surgical bypass in patients with SFA atherosclerotic occlusive disease. 59 Saxon and associates recently reported the outcomes of a clinical registry regarding long-term follow-up of primary Viabahn application in infrainguinal atherosclerotic occlusive disease. 18 During an 8-year period, the authors placed Viabahn in 87 limbs in 76 patients with symptomatic lowerleg arterial ischemic symptoms (mean lesion length 14.2 cm; 92% Ն7 cm in length; 42% total occlusions). Using duplex ultrasound surveillance, the authors reported primary, assisted primary, and secondary patency rates of 76%, 87%, and 93% at 1 year and 55%, 67%, and 79% at 4 years. The authors observed that primary patency was dependent on device diameter. Specifically, a remarkable primary patency rate of 82% was achieved at 4 years when device diameter was Ն7 mm in size. Based on their clinical practice preference, the authors described their preference of using Viabahn endoprosthesis only in vessels whose diameter is Ն4.5 mm in size. The authors noted that their treatment protocol was based on an assumption that there is a lower vessel diameter limit, below which the stent graft can represent a bulky mass that could lead to reduced patency and increased thrombotic complications. 18 A randomized prospective multicenter study is currently underway to evaluate the clinical performance of Viabahn endoprosthesis compared to bare metal nitinol stents in patients with long segments of femoropopliteal occlusive disease. This clinical investigation, also known as the VIBRANT trial, recently completed its patient enrollment in which a total of 148 patients were randomized from 15 institutions in the United States. 15, 60 Based on the preliminary study report, the mean lesion length was 18 cm with 58.1% being complete SFA occlusion. Two or more infrapopliteal vessel runoffs were present in 81.1% of cases, while 52% SFA lesions were deemed either moderately or severely calcified. No major safety differences have been demonstrated between the Viabahn and bare metal nitinol groups in a preliminary report of interim 6-month data. Treatment outcomes will include a 3-year follow-up with duplex ultrasound, and serial lowerextremity angiography will be used to define midterm and long-term patency rates. Quality-of-life data will also be analyzed using general and claudication-specific instruments. Based on the study hypothesis, the research investigators reported that divergence among the treatment groups in favor of the covered stent are not expected to emerge until after 1-year post-procedure. 15, 60 A recent device modification has led to the incorporation of heparin-bonded ePTFE graft material in the Viabahn endoprosthesis, which provides a theoretical advantage of continual heparin elution from the stent graft after intraluminal implantation. In the current FDA-approved iteration of the Viabahn endoprosthesis, the heparin molecules are bonded directly to the luminal surface of the graft, which leads to gradual heparin release from the graft surface as it maintains anti-thrombotic bioactivity. 61, 62 The heparinePTFE bonding technology has been studied previously in both animal experiments and clinical trials that uniformly validated the reduced graft thrombogenicity after intravascular implantation. 61, 63, 64 Although the heparin-bonded Viabahn endoprosthesis may confer a clinical advantage of lower postprocedural thrombotic complication, it remains to be determined whether this anti-thrombotic feature with heparin-bonded stent graft can lead to a clinical benefit of improvement in device patency.
Conclusions
Endovascular intervention of the femoropopliteal occlusive segment remains a clinical challenge, despite significant evolution in device refinement, technical refinement, and improved anticoagulation regimen. The introduction of the selfexpanding nitinol stent has dramatically increased the available armamentariums for interventionalists when treating patients with lower-leg arterial ischemic symptoms. The improved treatment outcomes with use of femoropopliteal stenting compared to balloon angioplasty has led to device approval by the FDA for lower-leg arterial implantation. The continual refinement of this endovascular technology has further widened other adjunctive treatment strategies, such as drug-eluting self-expanding stent and covered stent-graft treatment for femoropopliteal occlusive disease. Although all available randomized trials largely lauded the clinical efficacy of femoropopliteal artery stenting compared to balloon angioplasty in early results, the long-term clinical efficacy of this treatment strategy remains to be determined. Clearly, many considerations must be taken into account in order to achieve superior clinical outcomes with respect to femoropopliteal stenting, including appropriate patient and lesion selection and management of the patients' other relevant medical comorbidities. Undoubtedly, advances in endovascular interventions have gained increased acceptance of using this minimally invasive technique as a first-line treatment strategy for patients with symptomatic lower-leg ischemia. Further investigations with long-term follow-up are needed to validate the durability and sustained efficacy of this treatment modality.
